ALLMedicine™ Acral Lentiginous Melanoma Center
Research & Reviews 127 results
The Journal of Family Practice; Usatine RP, Heath CR
Jun 23rd, 2022 - THE COMPARISONA. Acral lentiginous melanoma on the sole of the foot of a 30-year-old Black woman. The depth of the lesion was 2 mm with a positive sentinel lymph node biopsy.B. Nodular melanoma on the shoulder of a 63-year-old Hispanic woman. The ...
Journal of the American Academy of Dermatology; Choi ME, Won CH et. al.
Jun 21st, 2022 - Clinical and Prognostic Influence of Tumor Diameter in Acral Lentiginous Melanoma.|2022|Choi ME,Won CH,Chang SE,Lee MW,Lee WJ,|
Journal of the American Academy of Dermatology; Brunsgaard E, Wu YP et. al.
May 10th, 2022 - Although there is a higher incidence of melanoma among non-Hispanic white individuals, melanoma is diagnosed at more advanced stages and associated with worse survival rates among individuals with skin of color (SOC). The proportion of melanoma su...
The British Journal of Dermatology; Di Carlo V, Stiller CA et. al.
Mar 30th, 2022 - CONCORD-3 highlighted wide disparities in population-based 5-year net survival during 2000-2014. Clinical evidence suggests marked international differences in the proportion of lethal acral and nodular subtypes. We aim to assess whether the diffe...
Dermatology (Basel, Switzerland); Gavillero A, García-Casado Z et. al.
Mar 30th, 2022 - Acral location of melanomas is associated with poor survival. It can be due, at least in part, to the fact that acral lentiginous melanoma, a distinct melanoma subtype, has a particular biological profile and a bad clinical behavior. However, sinc...
Clinicaltrials.gov 3 results
Feb 17th, 2022 - To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab
Feb 1st, 2022 - This was an open-label, single arm, Phase IIA, multi-center study to evaluate the Objective response rate (ORR) of dabrafenib and trametinib combination therapy in East Asian subjects that have BRAF V600 mutationpositive Stage IIIC (unresectable) ...
Jan 10th, 2020 - Immunotherapy with HD-IL-2 has produced durable benefit in 10% of patients with metastatic cutaneous melanoma. The antitumor activity of IL-2 has been limited at least in part by immunosuppressive and immune-regulatory forces within the tumor micr...
News 14 results
Feb 22nd, 2022 - NEW YORK (Reuters Health) - Race and socioeconomic status are associated with survival from acral lentiginous melanoma (ALM), according to a retrospective study. ALM is a type of melanoma that appears on the palms of the hands, the soles of the fe...
Oct 6th, 2021 - Jeffrey S. Weber, MD, PhD In recent years, advancements in the treatment of patients with metastatic melanoma have proceeded in 2 areas: targeted therapies and immunotherapies. There are now multiple choices in both modalities and, for targeted t...
MDedge Family Medicine;
Apr 22nd, 2021 - Fortunately, the dermoscopy images of these 2 small palmar lesions showed a pattern of pigmentation that aligned in the furrows and was consistent with benign palmar nevi. It is not uncommon to have nevi on the palms or soles of the feet, so it is.
Donna Bilu Martin, MD
Mar 17th, 2021 - Melanoma is a type of skin cancer that arises from melanocytes. According to the American Cancer Society, about 106,110 new melanomas will be diagnosed in the United States in 2021.
Dec 5th, 2020 - The CDK4/6 inhibitor palbociclib (Ibrance) exhibited preliminary activity in patients with acral lentiginous melanoma (ALM) associated with CDK-pathway aberrations, according to results of a small phase II trial that were reported at the 2019 ASCO...